

17 Tweets · 2021-06-01 12:36:45 UTC · **y** See on Twitter

rattibha.com 🖤

Hello #MedTwitter #nephtwitter

We recently had an interesting case-based discussion in @ASPNeph pathology webinar about #membranousnephropathy @IPNA_pedneph

Let's start with a poll!

Which of these is true about Membranous Nephropathy (MN)?

Correct Answer: D

- ◆ MN rare in children <12y (~1-3%)
- ◆ Incidence ↑ in adolescents (18-22%)
- ◆ Incidence of MN appears to be ↑ worldwide

PMC4074564

Presentation in peds:

- ◆ Most common: proteinuria +/- microscopic hematuria
- ◆ Nephrotic syndrome: 40-75%
- Hypertension: <10%
- ◆ Thromboembolic events: <5%
- Gross hematuria noted in some patients

Differences between pediatric and adult membranous nephropathy (MN)

	Pediatric MN	Adult MN	
Disease type/subtype:			
Proportion of primary nephrotic syndrome cases that are MN	< 5% (children) 5–20% (adolescents)	15–30%	
MN that is primary ("idiopathic")	Minority	Majority	
Proportion of primary MN that is PLA2R-associated	45% (more common in adolescents)	70-80%	
Demographic and clinical features:			
Male predominance	Variable	Yes	
Full nephrotic syndrome	40–75%	75%	
Microscopic hematuria	70-90% (can be macroscopic)	50%	
Hypertension	< 10%	30%	
Thromboembolic events	< 5%	10-20%	
Spontaneous remission	Common	30%	
Progressive renal impairment	< 25%	30-40%	
Pathological features:			
Mesangial deposits	Up to 50%	30%	
Segmental distribution of deposits	Occasional	Very rare	

PMC4074564

Types of MN:

- ◆ Primary: Antibody (Ab) to a known podocyte antigen
- ◆ Idiopathic: no identified target antigen
- ◆ Secondary: due to illness/exposure (75% of peds cases)
- ◆ Alloimmune: Ab to foreign antigen

Cause	Examples
Infections (1,2,27,56,90)	^b HBV, HCV, HIV, parasites (filariasis, schistosomiasis, malaria), leprosy, syphilis, hydatid disease, sarcoid
Malignancy (20% in patients >57, 4%<57) (1,2,14–18,55,58,66)	bSolid tumors (lung 26%, prostate 15%, hematologic [plasma cell dyscrasias, non-Hodgkin lymphoma, CLL] 14%, colon 11%), mesothelioma, melanoma, pheochromocytoma; some benign tumor
Autoimmune diseases (1,2,4,56–58,91)	bSLE (class V), thyroiditis, diabetes, rheumatoid arthritis, Sjogren syndrome, dermatomyositis, mixed connective tissue disease, ankylosing spondylitis, retroperitoneal fibrosis, renal allografts Anti-GBM disease, IgAN, ANCA-associated vasculitis IgG4 disease Membranous-like glomerulopathy with masked IgG κ deposits (90)
Alloimmune diseases (1,4,7,58,82)	Graft versus host disease, autologous stem cell transplants, bde novo MN in transplants/transplant glomerulopathy
Drugs/toxins (92)	NSAIDs and cyclooxygenase-2 inhibitors, gold, d-penicillamine, bucillamine, captopril, probenecid, sulindac, anti-TNFα, thiola, trimetadione, tiopronin
	Mercury, lithium, hydrocarbons, formaldehyde, ^b environmental air pollution (China) Cationic BSA (infants)


HBV, hepatitis B; HCV, hepatitis C; CLL, chronic lymphocytic leukemia; MN, membranous nephropathy; NSAIDs, non-steroidal antiinflammatory drugs.

PMC5460716

Which of the following are identified antigens for primary MN?

Correct Answer: D

Although PLA2R was the first antigen discovered in 2009 followed by THSD7A in 2014 (these are the most common antigens), all the above antigens have now been identified with distinct disease entities causing MN



PMC8054892

aMost of these associations are on the basis of multiple case reports or small series. Causative roles are implied but generally not proven. bCommon.

PLA₂R:

- ◆ Phospholipase A2 receptor (PLA2R) antibodies bind to antigens on podocytes
 - Present in 70% of adults with primary MN
- 45-50% of pediatric patients with primary MN
- Does not seem to be associated with secondary MN

PMC2762083

What is the classic histological pattern seen in MN?

Correct Answer: C

Classic MN Histology:

- ◆ LM: thickened GBM ("cheerios" appearance)
- Silver Stain: Spike pattern along GBM
- ◆ IF: IgG & Staining along GBM
- ◆ EM: finely granular electron dense deposits on subepithelial GBM




Fig. 1 Primary membranous nephropathy (MN) (hematoxylin and eosin; x200). Glomerular capillary walls are uniform with mild thickening (arrows)




Fig. 2 Primary membranous nephropathy (MN) (periodic acidmethenamine silver-Jones stain; x400). Characteristic spike-like epimembranous projections of basement membrane material on capillary walls (*arrows*)

Natural History:

- No specific peds data
- In adults course is remitting/relapsing and:
 - ~1/3 spontaneously remit without treatment
 - ~1/3 persistent proteinuria with preserved kidney function
 - ~1/3 progress to ESKD

PMC2887508

Management:

Due to rarity of disease and favorable prognosis without treatment, there are no RCTs comparing treatments of MN in children.

Treatment:

- ◆ Varies based on severity
- Remission may occur spontaneously
- Can take months/years to achieve

Management cont:

- Asymptomatic subnephrotic proteinuria:
 - Non-immunosuppressants (ACEi or ARBs)
- Nephrotic Syndrome, worsening proteinuria or antibody levels:
 - Immunosuppression (Rituximab, Tacrolimus)




Fig. 2 Algorithm for diagnosis and treatment decisions in pediatric membranous nephropathy. In cases of steroid-resistant nephrotic syndrome (SRNS), a diagnosis of MN may be made either by biopsy (tissue PLA2R) or with serum anti-PLA2R positivity (PLA2R-Ab). If a patient is known to have PLA2R-associated MN by virtue of biopsy staining for PLA2R within the deposits, or by seropositivity, only those nephrotic patients with high or rising antibody titers require immunosuppression;

if the antibody titers are decreasing, the patient can be followed with supportive, anti-proteinuric therapy. Patients who are PLA2R-negative on biopsy staining may have other antigen associations, such as THSD7A, exostosin (EXT1/2), or neural epidermal growth factor-like 1 protein (NELL-1) (see [58]). Patients with anti-THSD7A can be monitored as for anti-PLA2R. Treatment decisions in patients with non-PLA2R/THSD7A should be made on clinical grounds.

PMID: 31811540


MENTOR Trial:

- Randomized controlled trial
- ◆ 130 adult patients with MN and proteinuria > 5g/day
- ◆ Rituximab (Ritux) vs. Cyclosporine
- ◆ Ritux superior in achieving complete or Partial remission at 2y (60% vs. 20%)

MENTOR: MEmbranous Nephropathy Trial Of Rituximab







Results: in this randomized non-inferiority trial comparing cyclosporine to rituximab in the treatment of membranous nephropathy, rituximab was non-inferior to cyclosporine in inducing complete or partial proteinuria remission at 12 months and was superior in maintaining long-term proteinuria remission up to

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA et al. N Engl J Med 2019;381:36-46. VA by @Stones

PMID: 31269364

STARMEN Trial:

- Randomized open label controlled trial
- Adults with primary MN and persistent NS x 6months
- Steroid+CYC vs. Tacro+Ritux
- Complete remission higher with Steroid+CYC (60% vs 26%)

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. ► Methylprednisolone at **Immunological** 83.7% months 1, 3 and 5 60% N = 43response significantly 86 adult patients Cyclophosphamide at faster in Corticosteroidmonths 2, 4 and 6 Cyclophosphamide group. Relapses: 2.7% in **SECONDARY PRIMARY** 6 months Biopsy-proven At 24 **ENDPOINT** Corticosteroid-**ENDPOINT** observational Complete/Partial Complete **Primary Membranous** Cyclophosphamide months Remission Remission period group, 12% in Nephropathy Tacrolimus-Rituximab group. Oral tacrolimus (full-dose No differences in eGFR ≥45 ml/min/1.73m² for 6 months and tapering serious adverse 26% 58.1% Proteinuria >4 g/24h for another 3 months) events. Serum albumin ≤3.5 g/dl ► Rituximab 1g at month 6 **CONCLUSION:** Treatment with Corticosteroid-Cyclophosphamide induced significantly more remissions of nephrotic syndrome than treatment Fernández-Juárez et al, 2020

with Tacrolimus-Rituximab.

PMID: 33166580

Prognosis:

- Progression to ESKD in childhood is rare
- Spontaneous remission possible
- Younger children have better outcomes
- ◆ Primary diagnosis in 0.5 % of children with CKD and 0.4% on dialysis

https://www.naprtcs.org/system/files/2008_Annual_CKD_Report.pdf

Recurrence after transplant:

- Adult rates 7-45%
- ◆ anti-PLA2R Ab at the time of transplant ↑ risk
- No peds-specific data

PMID: 31811540

Now you are mem-BRAINY-ous about membranous nephropathy!

For a case-based clinical discussion with pathology expert login to @ASPNeph website, May webinar. Answer questions to get #MOC2credits #Membereducation #ASPNFOAMgroup

Thanks to @drM_sudha @RoshanPGeorgeMD @priti899

These pages were created and arranged by Rattibha services (https://www.rattibha.com)
The contents of these pages, including all images, videos, attachments and external
links published (collectively referred to as "this publication"), were created at the
request of a user (s) from Twitter. Rattibha provides an automated service, without
human intervention, to copy the contents of tweets from Twitter and publish them in an
article style, and create PDF pages that can be printed and shared, at the request of
Twitter user (s). Please note that the views and all contents in this publication are
those of the author and do not necessarily represent the views of Rattibha. Rattibha
assumes no responsibility for any damage or breaches of any law resulting from the
contents of this publication.